As per the terms of the contract, Sanofi is responsible to pay initial, approval and sales milestones to SkyePharma including single digit percentage on net sales.
The tie up allows Sanofi for pursuing marketing authorization applications for Flutiform across the region which includes Argentina, Brazil, Colombia, Mexico and Venezuela.
Presently, Sanofi is engaged in manufacturing Flutiform under an agreement with SkyePharma in Holmes Chapel, UK.
Additionally, Sanofi has got license for manufacturing Flutiform and supply it directly to its group companies for Mexico, Central and South America using certain ingredients and components supplied by SkyePharma.
SkyePharma CEO Axel Muller said they look forward to working with Sanofi as both manufacturer and licensee for Flutiform.